3D model is for representation purpose only.
.
.
GPLGIAGQ | Doxorubicin |
Identification | |
---|---|
ConjuPepDB ID | cpd01078 |
Smiles | |
Molecular weight | 1519.66 |
Molecular formula | C71H97N11O26 |
Chemical name | Peptide information |
Sequence (one letter) | GPLGIAGQ |
Length | 8 |
Peptide name | N/A |
External ID | |
---|---|
CAS number | 646065-65-8 |
Other information | |
---|---|
Application | Anticancer therapy |
Additional function | targeting integrin, improving antitumor effect |
Pharmacological class | anticancer |
Conjugate type | amide |
Linker | no |
Small molecule | Doxorubicin |
Small molecule CAS | 23214-92-8 |
Structure method | 1H and13C NMR, HPLC |
Calculated properties | |
---|---|
LogP | -3.59149 |
Rotatable bonds | 40 |
H bond donor | 14 |
H bond acceptor | 26 |
Polar surface area (PSA) | 541.32000 |
Citations | |||||
---|---|---|---|---|---|
ID | Title | Year | Authors | Journal | DOI |
In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin αvβ3 | 2008 | Ryppa, Claudia; Mann-Steinberg, Hagit; Fichtner, Iduna; Weber, Holger; Satchi-Fainaro, Ronit; Biniossek, Martin L.; Kratz, Felix | Bioconjugate Chemistry |